Clinical trials recruiting for Schizophrenia

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• "Extended" (Alternate Day) Antipsychotic Dosing
  NCT04478838 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• 40 Hz Visual Stimulation as an Intervention in Schizophrenia
  NCT06907420 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• 52-week Open Label Safety-Tolerability Study
  NCT07369154 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 23 locations
• A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse
  NCT07616999 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Bioequivalence Study of PP3M in Patients With Schizophrenia
  NCT07493551 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Case Series of Culturally-adapted CBTp for Black People in the UK
  NCT07252206 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years and older · Sex: All (male and female) · 1 location
• A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
  NCT06821945 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 2 locations
• A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
  NCT07459647 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 42 locations
• A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
  NCT07225712 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
  NCT06508450 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 34 Years · Sex: All (male and female) · 1 location
• A Novel Blood Test as a Biomarker in Mental Health
  NCT06856161 · Phase: Not specified · Ages: 19 Years and older · Sex: All (male and female) · 3 locations
• A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness
  NCT05537376 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
  NCT07423546 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
  NCT07230652 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
  NCT06929442 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 30 Years · Sex: All (male and female) · 2 locations
• A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
  NCT06729671 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Study of Brenipatide in Adult Participants With Schizophrenia
  NCT07410507 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 103 locations
• A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
  NCT07734493 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 10 locations
• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
  NCT07615426 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 8 locations
• A Study on the Preference of Risperidone Dosage Forms
  NCT06657430 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
  NCT07145918 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 7 locations
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
  NCT06540833 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female) · 67 locations
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
  NCT06887192 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 110 locations
• A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
  NCT07191483 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 15 locations
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 293 locations
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 44 locations
• A Study to Evaluate the Effect of KarXT on Urological Safety
  NCT07221877 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 13 locations
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
  NCT07105111 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
  NCT07288567 · Phase: Phase 3 · Ages: 13 Years to 17 Years · Sex: All (male and female) · 38 locations
• A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
  NCT06882785 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 56 locations
• A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
  NCT07424404 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · 91 locations
• A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
  NCT07061288 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 8 locations
• A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
  NCT06894212 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 73 locations
• A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
  NCT07434479 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female) · 2 locations
• Accelerated Neuromodulation Therapy and Neurocomputational Biomarkers in Individuals at Clinical High Risk for Psychosis
  NCT07786714 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 34 Years · Sex: All (male and female) · 1 location
• Accelerated Neuromodulation Therapy for Negative Symptoms of Schizophrenia
  NCT07428460 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
  NCT05491538 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Acceptability and Feasibility of a Brief Paranoia Intervention.
  NCT07350954 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years to 18 Years · Sex: All (male and female) · 1 location
• Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders
  NCT07395206 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Acetazolamide for Treatment Resistant Schizophrenia
  NCT04887792 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• Activities to Change Your Mood: A Test of the Acceptability and Initial Efficacy in Clinical Samples and Healthy Controls
  NCT06911723 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
  NCT04789915 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location
• Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment
  NCT02916810 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
  NCT03094429 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• An Integrated Neurophysiological Approach Toward the Early Detection of Psychiatric Disorders
  NCT06886945 · Phase: Not specified · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia
  NCT02640911 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
  NCT06351514 · Phase: Phase 3 · Ages: 21 Years to 65 Years · Sex: All (male and female) · 1 location
• Anti-Inflammatory Challenge in Schizophrenia
  NCT05823532 · Phase: Phase 4 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• Anticholinergic Deprescription in Schizophrenia
  NCT06562608 · Phase: Phase 4 · Ages: 40 Years to 70 Years · Sex: All (male and female) · 1 location
• App and Body Fat Scale in the Management of Overweight Patients
  NCT05866107 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Artificial Intelligence to Measure Adherence to Oral Medication
  NCT04046497 · Phase: Phase 4 · Ages: 15 Years to 40 Years · Sex: All (male and female) · 5 locations
• Asylumseekers Experiencing Paranoid Delusions: A Virtual Reality Study
  NCT06692530 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Autonomic Nervous System and Meridian Energy in Patients With Schizophrenia
  NCT06617104 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices
  NCT05982158 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis
  NCT07417904 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years to 30 Years · Sex: All (male and female) · 2 locations
• Bazedoxifene -Treatment for Women With Schizophrenia
  NCT04113993 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: Female · 1 location
• Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories
  NCT06978452 · Phase: Not specified · Ages: 9 Years to 25 Years · Sex: All (male and female) · 1 location
• Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia
  NCT07060066 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 60 Years · Sex: All (male and female) · 2 locations
• Biocollection on Peripheral Inflammation
  NCT05934474 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental Disorders
  NCT07479758 · Phase: Not specified · Ages: 18 Years to 45 Years · Sex: Female · 1 location
• Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode
  NCT05384392 · Phase: Not applicable (e.g. observational or device study) · Ages: 15 Years to 30 Years · Sex: All (male and female) · 5 locations
• Biomarkers in Clozapine-responding Schizophrenia
  NCT05316883 · Phase: Phase 4 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• Biomarkers to Enhance Early Schizophrenia Treatment
  NCT06969755 · Phase: Phase 4 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 5 locations
• Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
  NCT06740383 · Phase: Not specified · Ages: 18 Years to 40 Years · Sex: All (male and female) · 6 locations
• Brain Circuitry Therapeutics for Schizophrenia
  NCT06341517 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Brain Health and Exercise in Schizophrenia
  NCT01392885 · Phase: Not specified · Ages: 19 Years to 45 Years · Sex: All (male and female) · 1 location
• Brain Imaging of Cognition Inn Schizophrenia and Depression
  NCT04159662 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Brain Stimulation to the Hippocampus in Schizophrenia
  NCT07010614 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• CBT-CP for Veterans With SMI
  NCT06758414 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• CLOZAPINE Response in Biotype-1
  NCT04580134 · Phase: Phase 4 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 5 locations
• COMpassion for Psychiatric Disorders And Self-Stigma
  NCT05698589 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis
  NCT07001878 · Phase: Phase 4 · Ages: 18 Years to 25 Years · Sex: All (male and female) · 2 locations
• Cerebellar Modulation of Cognition in Psychosis
  NCT06107764 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• Cerebellar Stimulation and Cognitive Control
  NCT03217110 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 90 Years · Sex: All (male and female) · 2 locations
• Cerebellum-based Imaging Neural Markers for Antipsychotic Response
  NCT07483294 · Phase: Phase 4 · Ages: 15 Years to 40 Years · Sex: All (male and female) · 1 location
• Changing Lives and Changing Outcomes-9 at Worcester Recovery Center and Hospital
  NCT07359157 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Characterization of High-Level Cognitive Impairments in Patients With Neuropsychiatric Disorders
  NCT07295652 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
  NCT05276050 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 65 Years · Sex: All (male and female) · 1 location
• Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
  NCT05656469 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years to 70 Years · Sex: All (male and female) · 9 locations
• Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
  NCT05208190 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 7 locations
• Clozapine-related Immunodeficiency in Parkinsons Disease
  NCT06634641 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cognitive Behavioral Therapy for Sleep and Circadian Disturbances (CBT-I) in Treatment-Resistant Schizophrenia
  NCT06749444 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• Cognitive Remediation Method Using Rhythmic, Vocal and Corporal Musical Learning for Schizophrenia
  NCT07055204 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 60 Years · Sex: All (male and female) · 6 locations
• Cognitive Remediation Therapy for Schizophrenia: Effects on EEG and Emotional Regulation
  NCT06936397 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Cognitive Remediation in Forensic Mental Health Care
  NCT04610697 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Cognitive Strategies in Early Psychosis 1
  NCT07231497 · Phase: Phase 3 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 1 location
• Cognitive Strategies in Early Psychosis 2
  NCT07263022 · Phase: Phase 3 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 1 location
• Cognitive Training for Emotion Regulation in Psychotic Disorders
  NCT04414215 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis
  NCT07091344 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
  NCT04917302 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
  NCT05240976 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
  NCT04959201 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Combining mHealth and Nurse-delivered Care to Improve the Outcomes of People With Serious Mental Illness in West Africa
  NCT05703711 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Comparing Antipsychotic Medications in LBD Over Time
  NCT05590637 · Phase: Phase 4 · Ages: No age limits stated · Sex: All (male and female) · 4 locations
• Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)
  NCT06865937 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness
  NCT06641726 · Phase: Not specified · Ages: 18 Years to 110 Years · Sex: All (male and female) · 1 location
• Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
  NCT03794076 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting
  NCT05814913 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Database Registry for Neural Network Biomarkers in Psychosis
  NCT01409109 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study
  NCT06745479 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Schizophrenia often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Schizophrenia trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.